DelveInsight’s, “Sturge-Weber Syndrome – Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Sturge-Weber Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Sturge-Weber Syndrome Understanding
Sturge-Weber Syndrome: Overview
Sturge-Weber syndrome (SWS) is a rare disorder characterized by the association of a facial birthmark called a port-wine birthmark, neurological abnormalities, and eye abnormalities such as glaucoma. SWS can be thought of as a spectrum of disease in which individuals may have abnormalities affecting all three of these systems (i.e. brain, skin and eyes), or only two, or only one. Symptoms are usually present at birth (congenital), yet the disorder is not inherited and does not run in families. Some symptoms may not develop until adulthood. SWS is caused by a somatic mutation in the GNAQ gene. This mutation occurs randomly (sporadically) for no known reason. A diagnosis of SWS is based upon identification of characteristic symptoms (e.g. port-wine birthmark), a detailed patient history, a thorough clinical evaluation and a variety of specialized tests. A diagnosis may be straightforward in an infant with a port-wine birthmark, glaucoma, evidence of cerebral involvement and neuroimaging findings consistent with a diagnosis of SWS. Diagnosis can be more difficult in infants who have a port-wine birthmark, but no neurological symptoms. The treatment of SWS is directed toward the specific symptoms that are apparent in each individual. Laser therapy can lighten or remove the port-wine birthmark in affected individuals, even infants as young as one month old.

"Sturge-Weber Syndrome - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Sturge-Weber Syndrome pipeline landscape is provided which includes the disease overview and Sturge-Weber Syndrome treatment guidelines. The assessment part of the report embraces, in depth Sturge-Weber Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sturge-Weber Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Sturge-Weber Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Sturge-Weber Syndrome.

Sturge-Weber Syndrome Emerging Drugs Chapters
This segment of the Sturge-Weber Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Sturge-Weber Syndrome Emerging Drugs
• Sirolimus: Pfizer
Sirolimus, also known as rapamycin, is a macrolide compound that is used to coat coronary stents, prevent organ transplant rejection and treat a rare lung disease called lymphangioleiomyomatosis. It has immunosuppressant functions in humans and is especially useful in preventing the rejection of kidney transplants. It inhibits activation of T cells and B cells by reducing their sensitivity to interleukin-2 (IL-2) through mTOR inhibition. A Phase II/III evaluating sirolimus has been completed.
Further product details are provided in the report……..

Sturge-Weber Syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Sturge-Weber Syndrome drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Sturge-Weber Syndrome
There are approx. 4+ key companies which are developing the therapies for Sturge-Weber Syndrome. The companies which have their Sturge-Weber Syndrome drug candidates in the most advanced stage, i.e. Phase II/III include, Pfizer.
• Phases
DelveInsight’s report covers around 4+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Sturge-Weber Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Sturge-Weber Syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sturge-Weber Syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sturge-Weber Syndrome drugs.

Sturge-Weber Syndrome Report Insights
• Sturge-Weber Syndrome Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Sturge-Weber Syndrome Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Sturge-Weber Syndrome drugs?
• How many Sturge-Weber Syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Sturge-Weber Syndrome?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Sturge-Weber Syndrome therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Sturge-Weber Syndrome and their status?
• What are the key designations that have been granted to the emerging drugs?